logo
logo
OFIX stock ticker logo

Orthofix Medical Inc.

NASDAQ•OFIX
執行長: Mr. Geoffrey C. Gillespie
板塊: Healthcare
行業: Medical - Devices
上市日期: 1992-04-24
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
聯絡資訊
3451 Plano Parkway, Lewisville, TX, 75056, United States
214-937-2000
www.orthofix.com
市值
$496.59M
本益比 (TTM)
-5.4
27
股息率
--
52周最高
$17.28
52周最低
$10.24
52周範圍
30%
排名38Top 36.9%
4.3
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
一般 • 4.3 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025

財務儀表板

Q4 2025 數據

營業收入

$219.91M+0.00%
近4季度走勢

每股收益

-$0.06+0.00%
近4季度走勢

自由現金流

$17.61M+0.00%
近4季度走勢

2025 Annual 財報亮點

核心亮點

Net Sales Growth Achieved Total net sales reached $822.3M, reporting 2.9% growth; constant currency growth was 2.4% for the year.
Gross Margin Expansion Gross Margin improved 0.5 points to 68.8%; Net Loss narrowed by $33.8M compared to the prior year results.
Limb Reconstruction Sales Rise Global Limb Reconstruction sales increased 8.4% reported to $134.7M; U.S. growth led at 15.8% driven by investments.
R&D Spending Reduced Research and development expense decreased 10.6% to $65.8M following strategic discontinuation of M6 product lines.

關注風險

Healthcare Industry Consolidation Industry consolidation pressures pricing; GPOs/IDNs may exclude suppliers, materially affecting profitability and market access.
Integration of SeaSpine Merger Continued SeaSpine integration poses risk; failure to achieve intended synergies may adversely affect operating efficiencies and cost savings goals.
Pending Litigation Exposure Multiple litigation and arbitration matters pending, including former executives; accrual of $18.3M reflects ongoing financial uncertainty.
Regulatory Compliance Costs Extensive global regulation, especially E.U. MDR, requires significant ongoing costs to maintain compliance and market access.

未來展望

Focus on Profitable Growth Discontinuing M6 product lines to allocate resources toward more profitable growth opportunities across Global Spine segment.
Digital Platform Leverage Limb Reconstruction strategy emphasizes leveraging OrthoNext digital platform for planning and improving surgical outcomes.
Spine Technology Development Future growth driven by internally developed technologies and external acquisitions, focusing on cervical and thoracolumbar anatomy.
Liquidity Management Intend to retain consolidated earnings to finance continued growth; currently compliant with $15.0M unrestricted cash covenant.

同行對比

營業收入 (TTM)

VREX stock ticker logoVREX
$854.40M
+4.1%
OFIX stock ticker logoOFIX
$822.31M
+2.9%
AVNS stock ticker logoAVNS
$701.20M
+1.9%

毛利率 (最新季度)

ABSI stock ticker logoABSI
100.0%
+197.2pp
KALV stock ticker logoKALV
91.0%
+0.0pp
LAB stock ticker logoLAB
83.5%
-3.2pp

關鍵指標

股票代碼
市值
本益比 (TTM)
股東權益報酬率 (TTM)
負債率
MLTX$1.30B-5.2-67.1%17.8%
SVRA$1.14B-10.5-86.6%21.2%
BFLY$949.78M-12.2-35.3%6.9%

長期趨勢

近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
4.3%
溫和增長
4季度淨利複合增長率
N/M
盈利狀態轉變
現金流穩定性
75%
現金流波動較大

深度研究

下次財報:2026年5月4日
|
每股收益:-
|
營業收入:-
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表
過去12個月
無資料